You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 8, August 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Neurological Review
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Immunization
 •Hematology/ Hematologic Malignancies
 •Hematology, Other
 •Immunologic Disorders
 •Myasthenia Gravis
 •Neuromuscular diseases
 •Public Health
 •Alert me on articles by topic

Plasma Exchange in Neuroimmunological Disorders

Part 2. Treatment of Neuromuscular Disorders

Helmar C. Lehmann, MD; Hans-Peter Hartung, MD; Gerd R. Hetzel, MD; Olaf Stüve, MD; Bernd C. Kieseier, MD

Arch Neurol. 2006;63:1066-1071.

Plasma exchange is a well-established therapeutic procedure commonly used in many neurological disorders of autoimmune etiology. In this second part of our review, we assess the role of plasma exchange in the treatment of neuromuscular disorders. In Guillain-Barré syndrome and other immune-mediated neuropathic disorders, randomized controlled trials have demonstrated the therapeutic efficacy of plasma exchange. Myasthenia gravis and Lambert-Eaton syndrome represent neuromuscular disorders where plasmapheresis might be of potential efficacy.


Author Affiliations: Departments of Neurology (Drs Lehmann, Hartung, and Kieseier) and Nephrology (Dr Hetzel), Heinrich Heine University of Düsseldorf, Düsseldorf, Germany; and Department of Neurology, The University of Texas Southwestern Medical Center at Dallas (Dr Stüve).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies
Lehmann and Hartung
Brain 2008;131:1168-1170.
FULL TEXT  

Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions
Stuve et al.
Arch Neurol 2007;64:169-176.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.